Publicacions en què col·labora amb RAFAEL DELGADO VÁZQUEZ (26)

2023

  1. Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

    eBioMedicine

2022

  1. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11

2021

  1. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  2. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 3, pp. 738-742

2018

  1. Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis

    Journal of Virological Methods, Vol. 260, pp. 1-5

2016

  1. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Genetic barrier to resistance for dolutegravir

    AIDS reviews, Vol. 17, Núm. 1, pp. 56-64

  2. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  3. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade

    Archives of Virology, Vol. 159, Núm. 5, pp. 1079-1087

  2. Genetic barrier to resistance for dolutegravir

    AIDS Reviews, Vol. 17, Núm. 1, pp. 59-68

  3. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing

    Clinical Infectious Diseases, Vol. 59, Núm. 4, pp. 578-588

2012

  1. Lack of the detection of XMRV or polytropic MLV-related sequences in blood cells from HIV-1-infected patients in spain

    Journal of Acquired Immune Deficiency Syndromes, Vol. 59, Núm. 2, pp. 101-104

  2. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

    AIDS Reviews, Vol. 14, Núm. 3, pp. 208-217

2011

  1. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy

    Antiviral Therapy, Vol. 16, Núm. 5, pp. 725-732

  2. Sustained profile of transmitted drug resistance mutations for more than 10 years in an HIV type 1-infected patient

    AIDS Research and Human Retroviruses, Vol. 27, Núm. 1, pp. 41-45

2010

  1. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy

    Journal of Clinical Microbiology, Vol. 48, Núm. 5, pp. 1911-1912

  2. Genotypic determination of HIV tropism - Clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists

    AIDS Reviews, Vol. 12, Núm. 3, pp. 135-148

2009

  1. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258

  2. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152